EGFR and breast cancer: In addition, we identified c-METΔE14, HER2Y777L, EGFR-KDD, and HER4N855K as the most predominant driver mutants in these four tumors (Fig. 4b; Supplementary Fig. 14c), indicative of the convergent central role of receptor tyrosine kinases in both lung and breast cancer.